Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 25, 2021
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
[ Thu, Feb 25th 2021
] - WOPRAI
Jeffrey Hung Maintained (ACAD) at Buy with Increased Target to $65 on, Feb 25th, 2021
Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $60 to $65 on, Feb 25th, 2021.
Jeffrey has made no other calls on ACAD in the last 4 months.
There are 2 other peers that have a rating on ACAD. Out of the 2 peers that are also analyzing ACAD, 0 agree with Jeffrey's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Jeffrey
- Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $69 on, Wednesday, December 16th, 2020
- Danielle Brill of "Raymond James" Upgraded from Buy to Strong Buy and Held Target at $65 on, Monday, November 16th, 2020
